Pioglitazone (AD-4833)

For research use only.

Catalog No.S2590 Synonyms: U 72107

18 publications

Pioglitazone (AD-4833) Chemical Structure

CAS No. 111025-46-8

Pioglitazone (AD-4833, U 72107) is a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, used to treat diabetes; A weak activator for full-length hPPARα, but not full-length hPPARδ.

Selleck's Pioglitazone (AD-4833) has been cited by 18 publications

5 Customer Reviews

  • PPARγ activation, but not PPARα activation, increases β-klotho expression and FGF21 signaling. Protein (A) levels of β-klotho in hepatocytes after stimulation with or without 20μM Wy14643/Pioglitazone/Rosiglitazone for 24h

    Mol Nutr Food Res, 2017, doi: 10.1002/mnfr.201601075. Pioglitazone (AD-4833) purchased from Selleck.

  • Repression of BSEP gene expression upon treatment with reported BSEP inhibitors in human primary hepatocytes. BSEP mRNA expression was measured using real-time PCR in hepatocytes from at least three donors upon treatment with BSEP inhibitors as described in Materials and Methods (A). Dotted lines indicate 20% (dark) and 60% (light) BSEP repression compared with vehicle control (0.1% DMSO). A standard MTT assay as described in Materials and Methods was performed in human primary hepatocytes to monitor cytotoxicities associated with BSEP inhibitors at selected concentrations (B). All the data are expressed as mean±S.D. (n = 3).

    Drug Metab Dispos, 2014, 42(3):318-22.. Pioglitazone (AD-4833) purchased from Selleck.

  • RAW264.7 cells and hPBMCs were stimulated with RGZ (10 μmol/liter), pioglitazone (PGZ, 10 μmol/liter), or both. The integrin αV and β5 mRNA (I) or protein (J) levels were examined by RT-qPCR or immunoblotting.

    J Biol Chem, 2019, 293(43):16572-16582. Pioglitazone (AD-4833) purchased from Selleck.

  • Macrophage (MΦ) staining in representative sections of pancreatic islets from mice fed (A) normal chow, (B) high-fat diet (HFD), (C) HFD + clodronate, and (D) HFD + pioglitazone. β-Cells were immunostained with anti-insulin Ab (green) and MΦs with anti-F4/80 Ab (red). Nuclei were stained in blue. Scale bar, 50 μm. Most of the F4/80-positive cells are detected within the islets.

    Am J Physiol Endocrinol Metab, 2016, 311(4):E763-E771. . Pioglitazone (AD-4833) purchased from Selleck.

  • Caco2 cells were treated with different concentrations (10 or 20 lg/ml) of a PPARc agonist (pioglitazone) (d) for 6 h without UA stimulation. SIRT1, PGC-1, PPARc and ABCG2 were measured, and quantitative analyses of the results are shown. The data are presented as the mean ± SEM. *p<0.05 and **p<0.01 compared with the control group.

    Endocrine, 2016, 53(2):443-52. . Pioglitazone (AD-4833) purchased from Selleck.

Purity & Quality Control

Choose Selective PPAR Inhibitors

Biological Activity

Description Pioglitazone (AD-4833, U 72107) is a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, used to treat diabetes; A weak activator for full-length hPPARα, but not full-length hPPARδ.
Targets
PPARγ [2]
In vitro

Pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYP3A4 in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CV-1 NVvkeWI{TnWwY4Tpc44h[XO|YYm= M{PnVWlvKH[rdILvJJRz[W6|Y4LpdJRqd26jbDDhZ5RqfmG2aX;uJI9nKFCncn;4bZNwdWVicILvcIln\XKjdH;yJIFkfGm4YYTl[EBz\WOncITvdkBo[W2vYTCoVHBCWiliZYjwdoV{e2WmIHnuJGNXNTFiY3XscJMtKEWFNUC9NE43Qc7:TR?= NF;rW3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi96NUe2PVA4Lz56NUe2PVA4RC:jPh?=
3T3-L1 M37SZ2Z2dmO2aX;uJIF{e2G7 MoTNSYZn\WO2aY\lJINwdmOnboTyZZRqd25iZn;yJFUxLSCnbnjhcoNmdWWwdDDv[kBqdnO3bHnuMYlv\HWlZXSgeJJq\2y7Y3XybYRmKGGlY4XteYxifGmxbjDpckA{XDNvTEGgZ4VtdHNuIFXDOVA:OC5zNt88US=> NH\CV|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97NUm5NlQyLz57NUm5NlQyRC:jPh?=
CV-1 M4LxXmZ2dmO2aX;uJIF{e2G7 NF7ONXZC[3SrdnH0bY9vKG:oIIDldo95cXOxbXWgdJJwdGmoZYLheI9zKGGldHn2ZZRm\CC{ZXPldJRweiCpYX3tZUBu\WG|dYLl[EBjgSCrbnT1Z5Rqd25ib3[gOVAmKG:oIH3hfIlufW1iYXzrZYxqdmVicHjvd5Bp[XSjc3WgZYN1cX[rdImsJJRz[W6|ZnXjeIlwdiCjc4PhfUBqdiCFVj2xJINmdGy|LDDFR|UxRTBwNUi4PFTPxE1? MlH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTh|Nk[yNEc,QTh|Nk[yNFww[T5?
CV-1 MmqzSpVv[3Srb36gZZN{[Xl? MnTOUYF5cW2jbDDy[ZBwenSncjDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCncn;4bZNwdWVicILvcIln\XKjdH;yJIFkfGm4YYTl[EBz\WOncITvdkBo[W2vYTDHZYw1KGOqaX3ldolkKGmwIITyZY5{cWWwdHz5JJRz[W6|ZnXjeIVlKEOYLUGgZ4VtdHNiYomg[pVv[3Srb37hcEBie3OjeT6sJGVEPTB;MD61PO69VQ>? MkW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF5MkC4OVQoRjFzN{KwPFU1RC:jPh?=
HEK293 NXvBVWUxTnWwY4Tpc44h[XO|YYm= NV\6Smo4SWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhemWlZYD0c5IhcW62ZYLhZ5Rqd25id3n0bEB{fGW{b3nkJJJm[2WydH;yJINw[WO2aY\heI9zNTFiYomgSXlHWCCkYYPl[EBz\XCxcoTldkBo\W6nIHHzd4F6 MnPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ4OECxOVkoRjF4NkiwNVU6RC:jPh?=
HEK293 MkPYSpVv[3Srb36gZZN{[Xl? MUXB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDy[YNmeHSxcjDpcpRmemGldHnvckB4cXSqIILleIlvd2mmIGitdoVk\XC2b4KgZYxxcGFiYomgSXlHWCCkYYPl[EBz\XCxcoTldkBo\W6nIHHzd4F6 MmPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ4OECxOVkoRjF4NkiwNVU6RC:jPh?=
CV1 Mm\6SpVv[3Srb36gZZN{[Xl? M3KzfXRz[W6|YXP0bZZifGmxbjDv[kBRWEGUZ3HtcYEhcW5iQ2[xJINmdGy|LDDFR|UxRTBwNUZOwG0> M4WwRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEKxO|Y6Lz5zNkiyNVc3QTxxYU6=
Cos7 Mlz5SpVv[3Srb36gZZN{[Xl? MkjYNVQhcHK| M3rSfHRz[W6|YXP0bZZifGmxbjDv[kBpfW2jbjDQVGFT\2GvbXGgUGJFKGW6cILld5Nm\CCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEd3N5IHPlcIx{KGOxLYTyZY5{\mWldHXkJJdqfGhiZoXz[YQhT0GOND3ERmQh[W[2ZYKgNVQhcHK|IHL5JGR2[WxvR3zvJGx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjQQvF2= NWXNfnBzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzNFc6QDFpPkKwN|A4QThzPD;hQi=>
3T3L1 MWnGeY5kfGmxbjDhd5NigQ>? NGrQenIyODBidX3vcE9N NILoTIZKdmO{ZXHz[UBqdiCSUFHS[4FudWFibWLORUBt\X[nbIOgbY4hdW:3c3WgN3Q{VDFiY3XscJMh[XRiMUCwJJVud2xxTDDifUBTXC2SQ2K= NVLCeo46RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPVI3PDVpPkKwN|kzPjR3PD;hQi=>
CHO MlvGSpVv[3Srb36gZZN{[Xl? NVfwR41SSWO2aY\heIlwdiCxZjDHZYw1NXSjZ3fl[EBpfW2jbjDQVGFT\2GvbXGg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4yPM7:TR?= NUCwb|V7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2OVY1QTRpPkKwOlU3PDl2PD;hQi=>
HEK293T NH3p[ldHfW6ldHnvckBie3OjeR?= NXH1Zo12OSC3TR?= M4HHVFI1KGi{cx?= NXK0W48{WGG{dHnhcEBi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZU1NSkRiZYjwdoV{e2WmIHnuJGhGUzJ7M2SgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKHKnY3XweI9zKHS{YX7zZYN1cX[jdHnvckBifCBzIIXNJIFnfGW{IEK0JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk> NWDIbJhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwN|AzPjNpPkKxNFMxOjZ|PD;hQi=>
COS-1 NUnmVWdxTnWwY4Tpc44h[XO|YYm= NUPvTGRQSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBEV1NvMTDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfhcFQh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUCuN|nPxE1? M{fxXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUOwOlQ6Lz5{MUGzNFY1QTxxYU6=
CHO MWfGeY5kfGmxbjDhd5NigQ>? M{PJeFI1KGi{cx?= MX7QZZJ1cWGuIHHnc45qe3RiYXP0bZZqfHliYYSgbJVu[W5iUGDBVodidW2jIHX4dJJme3OnZDDpckBEUE9iY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCJYXy0MZJme3CxboPpeoUhdHWlaX\ldoF{\SC{ZYDvdpRmeiCybHHzcYllKGGodHXyJFI1KGi{czDifUB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5|Od88US=> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5N{i3OUc,OjF|N{e4O|U9N2F-
COS7 M{PJWWZ2dmO2aX;uJIF{e2G7 M4nHfm1w\HWuYYTpc44hd2ZiaIXtZY4hWFCDUnfhcY1iNUyERDDlfJBz\XO|ZXSgbY4h[W[{aXPhckBoemWnbjDtc45s\XliQ1;TO{Bk\WyuczDjc{11emGwc3\lZ5Rm\CC5aYToJGdidDRiYYPz[ZN{\WRiYYOgZYN1cX[jdHnvckBw\iC2cnHud4FkfGm4YYTpc44h[WO2aY\peJkh[nlibIXjbYZmemG|ZTDhd5NigSxiRVO1NF0xNjQQvF2= NIXKdVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi3N|A4OCd-MkG4O|MxPzB:L3G+
Sf21 MoLsSpVv[3Srb36gZZN{[Xl? MoXNTY5pcWKrdHnvckBw\iCqdX3hckBDW0WSIHX4dJJme3OnZDDpckBxdGG|bXGgcYVu[nKjbnWgeoV{cWOuZYOgc4YhW2Z{MTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGWUD3k[ZBmdmSnboSgX|NJZXSjdYLvZ4hwdGG2ZTD1dJRic2VuIFnDOVA:OC5|zszN M1LG[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[1OlI{Lz5{MUm2OVYzOzxxYU6=
Sf21 NX\OU21oTnWwY4Tpc44h[XO|YYm= MVjJcohq[mm2aX;uJI9nKFOycnHneYUuTGG5bHX5JJJifCCEc3XwJIV5eHKnc4Pl[EBqdiCybHHzcYEhdWWvYoLhcoUhfmW|aXPs[ZMhd2ZiU3[yNUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHUVE1l\XCnbnTlcpQhYzOKXYTheZJw[2ixbHH0[UB2eHSja3WsJGlEPTB;Mt88US=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4NU[yN{c,OjF7NkW2NlM9N2F-
HepG2 NX7GRVg3TnWwY4Tpc44h[XO|YYm= NH;zZZkzOCCqcoO= NFP6U45C\2:waYP0JIFkfGm4aYT5JIF1KEeDTESteIFo\2WmIHj1cYFvKFCSQWLnZY1u[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6g[ZhxemW|c3XkJIlvKEincFeyJINmdGy|IHHzd4V{e2WmIHHzJJRz[W6|YXP0bZZifGmxbjDh[pRmeiB{MDDodpMh[nliYnX0ZU1o[WyjY4Tvd4ll[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;MD61O:69VQ>? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN2MUW3N{c,OjJ|NEG1O|M9N2F-
HEK293 MYPGeY5kfGmxbjDhd5NigQ>? NYXZbZhoOThiaILz MmHVWJJidnOjY4TpeoF1cW:wIH;mJIh2dWGwIFfBUFQu\nW|ZXSgVHBCWmejbX3hJIxq\2GwZDDibY5lcW6pIHTvcYFqdiC2cnHud4Zm[3SnZDDpckBJTUt{OUOgZ4VtdHNiYX\0[ZIhOThiaILzJIJ6KGS3YXygcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvQM7:TR?= Mm\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMEK4PVEoRjJ|MUCyPFkyRC:jPh?=
COS7 M{HW[GZ2dmO2aX;uJIF{e2G7 MXPUdoFve2GldHn2ZZRqd25ib3[gS2FNPC2odYPl[EBpfW2jbjDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKHS{YX7z[oVkfGWmIHnuJIFnemmlYX6g[5Jm\W5ibX;ub4V6KEORU{egZ4VtdHNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvOs7:TR?= Ml3tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzM{C5OlQoRjJ|MUOwPVY1RC:jPh?=
THP1 MWfBcpRqcW6obHHtcYF1d3K7IHHzd4F6 NH;EfZoyKGi{ NVT3cJhISW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCqdX3hckBVUFBzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWE2DLXnu[JVk\WRiTVPQMVEhe2WlcnX0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhOSCqcjDwdolweiCSTVGtZ4hidGynbnflJI1m[XO3cnXkJIFnfGW{IES4JIhzeyCkeTDFUGlUSSxiSVO1NF0yQC56NN88US=> MljCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MUGwPVIoRjJ|OEGxNFkzRC:jPh?=
THP1 M{HpVmFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? M1fJPFIhcHK| NFPVNmNCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKGi3bXHuJHRJWDFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBRVUFvaX7keYNm\CCPQ2CtNUB{\WO{ZYTpc44hcW6ldXLheIVlKG[xcjCyJIhzeyCycnnvdkB1dyCSTVGgZ4hidGynbnflJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDFUGlUSSxiSVO1NF0yQC54zszN MoS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3M{GyNlcoRjJ2NUOxNlI4RC:jPh?=
HEK293 NX3oW5BHTnWwY4Tpc44h[XO|YYm= MXixNEB2VQ>? M2H4PVI1KGi{cx?= NW\qZ|NvXHKjboPhZ5RqfmG2aX;uJI9nKFCSQWKt[4FudWFiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGG2IEGwJJVOKGGodHXyJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl? NUXB[YNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PVAxQTBpPkK0PFkxODlyPD;hQi=>
HEK293 MXzGeY5kfGmxbjDhd5NigQ>? NEXEbFgyQCCqcoO= MVPB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOThiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkKx{txO NIXBN2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzN|g2Oyd-MkWzN|M5PTN:L3G+
COS7 Mk\oSpVv[3Srb36gZZN{[Xl? Mn;aWJJidnOjY4TpeoF1cW:wIH;mJIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO|ZXSgbY4hSW[{aXPhckBoemWnbjDtc45s\XliQ1;TO{Bk\WyuczDpcoN2[mG2ZXSgc5Zmem6rZ3j0JIJ6KGS3YXyt[4xwKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkNOwG0> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV7NUe0PUc,OjZ3OUW3OFk9N2F-
THP1 MUTGeY5kfGmxbjDhd5NigQ>? M{TqdVExKHWP MoHnNlQhcHK| NUHqfXNsXXC{ZXf1cIF1cW:wIH;mJGFDS0FzIH3SUmEh\XiycnXzd4lwdiCrbjDoeY1idiCWSGCxJINmdGy|IHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCzUFPSJI1mfGixZDDy[YxifGm4ZTD0c{Bkd262cn;s M1fsNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkKwNFY2Lz5{N{KyNFA3PTxxYU6=
THP1 MVfGeY5kfGmxbjDhd5NigQ>? NVLBcnJTOTBidV2= M4LONFI1KGi{cx?= NUTnco5JXXC{ZXf1cIF1cW:wIH;mJGFDS0dzIH3SUmEh\XiycnXzd4lwdiCrbjDoeY1idiCWSGCxJINmdGy|IHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCzUFPSJI1mfGixZDDy[YxifGm4ZTD0c{Bkd262cn;s NX\KVIc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyNlAxPjVpPkK3NlIxODZ3PD;hQi=>
COS7 NF7nNnNHfW6ldHnvckBie3OjeR?= NWrvfJhjPDJiaILz MVzUdoFve2GldHn2ZZRqd25ib3[gS2FNPC2odYPl[EBpfW2jbjDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGW6cILld5Nm\CCrbjDB[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{KGGodHXyJFQzKGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlXPxE1? NXy1T4Q3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1OlAzQDJpPkK3OVYxOjh{PD;hQi=>
COS7 MoqxSpVv[3Srb36gZZN{[Xl? MYK0NkBpenN? Mmi1WJJidnOjY4TpeoF1cW:wIHH0JGdidDRiZoXz[YQhWFCDUnfhcY1iKEyERDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBC\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy|IHHmeIVzKDR{IHjyd{BjgSCudXPp[oVz[XOnIHHzd4F6NCCHQ{WwQVAvOzMQvF2= NHqwTYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W2PVE6PSd-Mke1OlkyQTV:L3G+
COS7 M1;IcGZ2dmO2aX;uJIF{e2G7 NETmeGk1OiCqcoO= MknCWJJidnOjY4TpeoF1cW:wIH;mJGdidDRiZoXz[YQhcHWvYX6gVHBCWmejbX3hJGxDTCCneIDy[ZN{\WRiaX6gRYZzcWOjbjDndoVmdiCvb37r[ZkhS0:VNzDj[YxteyCjZoTldkA1OiCqcoOgZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4{QM7:TR?= M2GwTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUG4PVk1Lz5{N{mxPFk6PDxxYU6=
PC3 MnP2SpVv[3Srb36gZZN{[Xl? Mlf4OVAhfU1? M1LiTlI1KGi{cx?= M3\OPWlv[3KnYYPlJIlvKHB{MTjXRWYyMSCycn;0[YlvKGW6cILld5Nqd25iaX6gbJVu[W5iUFOzJINmdGy|IHH0JFUxKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NUHLUo0xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizPVUzOjBpPkK4N|k2OjJyPD;hQi=>
MDA-MB-231 NWjqZ2x{TnWwY4Tpc44h[XO|YYm= Mm\GOVAhfU1? NH\Nc4szPCCqcoO= MUTJcoNz\WG|ZTDpckBxOjFqV1HGNUkheHKxdHXpckBmgHC{ZYPzbY9vKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiNUCgeW0hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NGLucIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO5OVIzOCd-MkizPVUzOjB:L3G+
HEK293 NE[4[YVHfW6ldHnvckBie3OjeR?= MmfwNlQhcHK| M1LVbnRz[W6|YXP0bZZifGmxbjDhZ5Rqfmm2eTDheEBI[Wx2IH\1d4VlKG[3bHygcIVv\3SqIHj1cYFvKFCSQWLnZY1u[SCOQlSg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDh[pRmeiB{NDDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUGuNe69VQ>? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4NUC5PUc,Ojh2NkWwPVk9N2F-
HEK293 MlXkSpVv[3Srb36gZZN{[Xl? NHzrTWM1KGi{cx?= NWHXR2VIXHKjboPy[ZBz\XO|aX;uJIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWG5H[WyyaHGgbY5lfWOnZDDOSk1s[XCyYVKgdJJwdW:2ZYKgZYN1cX[rdImgdJJmfHKnYYTl[EBnd3JiNDDodpMh\m:ubH;3[YQh[nliVF7GZYxxcGFic4TpcZVt[XSrb36gZYZ1\XJiMzDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyPUKy{txO MnH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkWwPVkoRjJ6NE[1NFk6RC:jPh?=
SCC15 NEDvN3dEgXSxdH;4bYNqfHliYYPzZZk> NHj5[XQ2OCC3TR?= Mk\PNlQhcHK| MlW1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2NEOTViY3XscJMhfHKjboPm[YN1\WRid3n0bEBRWEGUYXzwbIEhe2mUTlGgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEWwJJVOKGGodHXyJFI1KGi{czDifUBz\XOjeoXybY4hemWmdXP0bY9vKGG|c3H5 NGL3Sos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUCzNVA3Oyd-MkmwN|ExPjN:L3G+
SCC15 NGXN[3BEgXSxdH;4bYNqfHliYYPzZZk> M3L5VFUxKHWP MWiyOEBpenN? NISzO3VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUS0NzNTDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKFCSQWLi[ZRiKHOrUl7BJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDC1NEB2VSCjZoTldkAzPCCqcoOgZpkhemW|YYr1dolvKHKnZIXjeIlwdiCjc4PhfS=> M3y3Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEOxNFY{Lz5{OUCzNVA3OzxxYU6=
HepG2 M3W0[GZ2dmO2aX;uJIF{e2G7 MV2yOEBpenN? MYrB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDhZ5RqfmG2aX;uJI9nKFCSUlWgbY5kfWKjdHXkJIZweiB{NDDodpMh[nliZIXhcEBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5{NN88US=> NWD3VFB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFE5PDZpPkOwNFAyQDR4PD;hQi=>
HEK293BENA M3nFVGZ2dmO2aX;uJIF{e2G7 MVqyOEBpenN? NGm2dXFVemGwc3HjeIl3[XSrb36gc4YhT0GOND3meZNm\CCqdX3hckBRWEGUZ3HtcYEhfHKjboPm[YN1\WRiaX6gTGVMOjl|QlXORUBk\WyuczDh[pRmeiB{NDDodpMh[nlic4TlZYR6KGeubz3seYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9Nk4xPTQQvF2= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN3MUmzN{c,OzB|NUG5N|M9N2F-
HEK293 M4K2UGZ2dmO2aX;uJIF{e2G7 NEHrPXMyQCCqcoO= NWHJWII5XHKjboPhZ5RqfmG2aX;uJI9nKGi3bXHuJIZ2dGxibHXu[5RpKFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGGodHXyJFE5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZoF{\WRibIXtbY5me2OnbnPlJIF{e2G7LDDFR|UxRTBwMd88US=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4MkezPUc,OzB|NkK3N|k9N2F-
293H MWXGeY5kfGmxbjDhd5NigQ>? NYH4TYZ6OTZiaILz NF;ufWxVemGwc3HjeIl3[XSrb36gc4YhT0GOND3ERmQh\nW|ZXSgbJVu[W5iUGDBVodidW2jIHzp[4Fv\CCkaX7kbY5oKGSxbXHpckBmgHC{ZYPz[YQhcW5iVVHTMYJt[SCKRVygNlk{UCClZXzsd{BxemWrbnP1ZoF1\WRiZn;yJFE3KGi{czDmc4xtd3enZDDifUBHWkWWIIP1ZpN1emG2ZTDh[IRqfGmxbjDhcoQhdWWjc4Xy[YQh[W[2ZYKgNkBpenNiYomgWHIuTlKHVDDhd5NigSxiRVO1NF0xNjB7ON88US=> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUC5O{c,OzB2MkmwPVc9N2F-
3T3L1 NULKUIt1TnWwY4Tpc44h[XO|YYm= NWrjemRFOTBidV2= NXrPcWEzOjRiaILz M4f6OWFod26rc4SgZYN1cX[rdImgZZQhWFCDUnfhcY1iKGmwIH3veZNmKDOWM1yxJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEGSMTDtVm5CKGW6cILld5Nqd25iYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFO\QmKg[5Jm\W5iZInlJIJie2WmIGLUMXBEWiCjbnHsfZNqew>? M3rQWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUm0OFMzLz5|MEW5OFQ{OjxxYU6=
3T3L1 MXfGeY5kfGmxbjDhd5NigQ>? M2XJfVExKHWP M17SdFI1KGi{cx?= M2XPXWFod26rc4SgZYN1cX[rdImgZZQhWFCDUnfhcY1iKGmwIH3veZNmKDOWM1yxJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEOGM{[gcXJPSSCneIDy[ZN{cW:wIHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCVWVLSJIdz\WWwIHT5[UBj[XOnZDDSWE1RS1JiYX7hcJl{cXN? MoTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3OUS0N|IoRjNyNUm0OFMzRC:jPh?=
3T3L1 MULGeY5kfGmxbjDhd5NigQ>? MXixNEB2VQ>? MWGyOEBpenN? MlHaRYdwdmm|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5ibX;1d4UhO1R|TEGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hT2y3dESgcXJPSSCneIDy[ZN{cW:wIHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCVWVLSJIdz\WWwIHT5[UBj[XOnZDDSWE1RS1JiYX7hcJl{cXN? NGCzTJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEW5OFQ{Oid-M{C1PVQ1OzJ:L3G+
3T3L1 M3j2cGZ2dmO2aX;uJIF{e2G7 NY\HWHF1OTBidV2= MoHiNlQhcHK| NES2UFFC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDtc5V{\SB|VEPMNUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjZHnwc45m[3SrbjDtVm5CKGW6cILld5Nqd25iYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFO\QmKg[5Jm\W5iZInlJIJie2WmIGLUMXBEWiCjbnHsfZNqew>? NGnkWWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEW5OFQ{Oid-M{C1PVQ1OzJ:L3G+
stem cells M{fLPGZ2dmO2aX;uJIF{e2G7 NEm5TGw2KGSjeYO= NUHxO|JtUW6mdXP0bY9vKG:oIHHkbZBw\2WwZYPpd{BqdiCqdX3hckBjd26nIH3hdpJwfy2mZYLpeoVlKG2nc3XuZ4h6dWGuIIP0[Y0h[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iYXTpdI9v\WO2aX6gdJJw\HWldHnvckBu\WG|dYLl[EBwdiCmYYmgOUBqdiCycnXz[Y5k\SCxZjDJSHgh[nliRVzJV2EtKEWFNUC9NE4{Pc7:TR?= NUDPWWl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C2O|I3QThpPkOwOlczPjl6PD;hQi=>
HEK293T NUPRZoNyTnWwY4Tpc44h[XO|YYm= M4X5NVE5KGi{cx?= MnfEWJJidnOjY4TpeoF1cW:wIH;mJIZ2dGxibHXu[5RpKGi3bXHuJHBRSVKpYX3tZVIh\XiycnXzd4VlKGmwIFjFT|I6O1RiY3XscJMh[29vZYjwdoV{e2mwZzDQVHJGKGGodHXyJFE5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5{Nd88US=> NVe1RoR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C2O|Y4PDFpPkOwOlc3PzRzPD;hQi=>
HEK293T M1PzSGZ2dmO2aX;uJIF{e2G7 M3jqR|E5KGi{cx?= MoP6WJJidnOjY4TpeoF1cW:wIH;mJINpcW2ncnnjJGdidDRieXXhd5QhTEKGIH\1d4VlNVCSQWLnZY1u[SCOQlSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hUEWNMkmzWEBk\WyuczDjc{1mgHC{ZYPzbY5oKFCSUlWgZYZ1\XJiMUigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlM2|ryP NFPC[289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|ME[3Olc1OSd-M{C2O|Y4PDF:L3G+
HepG2 NX70c|ZoTnWwY4Tpc44h[XO|YYm= MXOzNEB2VQ>? NE\5NJJDcW6maX7nJIFn\mmwaYT5JJRwKE6DRkGgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hcHWvYX6gTIVxTzJiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBucXSxY3jvcoRzcWGuIILld5BqemG2aX;uJIF1KDNyIIXN MnLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB5N{CxOVQoRjNyN{ewNVU1RC:jPh?=
HepG2 NED6VJhHfW6ldHnvckBie3OjeR?= M37yfVMxKHWP NED1SlNDcW6maX7nJIFn\mmwaYT5JJRwKE6DRkGgbY4hcHWvYX6gTIVxTzJiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBucXSxY3jvcoRzcWGuIILld5BqemG2aX;uJIF1KDNyIIXN MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODd5MEG1OEc,OzB5N{CxOVQ9N2F-
COS7 M4HGUmZ2dmO2aX;uJIF{e2G7 NFPIVJU{QSCqcoO= NYm4NZRpXHKjboPhZ5RqfmG2aX;uJI9nKEejbESt[pV{\WRiaIXtZY4hWFCDUnfhcY1iKHS{YX7z[oVkfGWmIHnuJGNQWzdiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCyR1HMOU1VUy2yR1yzJIFv\CCyUnXucoltdGFvQ13WJIlv[3WkYYTl[EBnd3JiM{mgbJJ{KGK7IHT1ZYwhdHWlaX\ldoF{\SC{ZYDvdpRmeiCjc4PhfUwhTUN3ME2xMlTPxE1? M4LuRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNkS4NVI2Lz5|MU[0PFEzPTxxYU6=
K562-IMA[r] MlnySpVv[3Srb36gZZN{[Xl? MVexNEB2VQ>? MkjyO|IhcHK| M{HmPWlv\HWldHnvckBw\iC|ZX7zbZRqgmG2aX;uJJRwKGmvYYTpcoljNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHnuJIlu[XSrbnniMZJme2m|dHHueEBpfW2jbjDLOVYzNUmPQWvyYUBk\WyuczDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDheEAyOCC3TTDh[pRmeiB5MjDodpMhcW5icILld4Vv[2Vib3[gNUB2VSCrbXH0bY5q[iCkeTDwdo9xcWSrdX2gbY9lcWSnL2TybZRwdi2[MUCwJIR6\SCkYYPl[EBHSUOVIHHuZYx6e2m| NVjvSI5PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G2OFgyOjVpPkOxOlQ5OTJ3PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Phopsho-RB / RB; 

PubMed: 25264247     


Pioglitazone treatment causes a decrease in the levels of phosphorylated RB in both NCI-H2347 and NCI-H1993 cells within 24 hours.

p-VEGFR2 / VEGFR ; 

PubMed: 29972411     


Representative western bolotting trace of VEGFR-2 and phospho-VEGFR-2 (Tyr1175) protein levels in rat neonatal cardiomyocytes under hypertrophic stimuli, and treated with 0, 10, 20 (µM) pioglitazone for 24 hours.

25264247 29972411
In vivo Pioglitazone significantly attenuates left ventricular (LV) cavity dilatation and dysfunction by echocardiography as well as LV end-diastolic pressure in mice with extensive anterior myocardial infarction. Pioglitazone partially normalizes LV dP/dt(max) and dP/dt(min), indices of LV contractile function, which are significantly reduced in MI mice. [2] Pioglitazone results in a reduced activation of microglia, reduced induction of iNOS-positive cells and less glial fibrillary acidic protein positive cells in both striatum and substantia nigra pars compacta of MPTP mouse model of Parkinson's disease. Pioglitazone almost completely blocks staining of TH-positive neurons for nitrotyrosine, a marker of NO-mediated cell damage. [3] Pioglitazone (approximately 20 mg/kg/day) attenuates the MPTP-induced glial activation and prevents the dopaminergic cell loss in the substantia nigra pars compacta (SNpc) in MPTP mouse model of Parkinson's disease. [4] Pioglitazone results in a reduction in the number of activated microglia and reactive astrocytes in the hippocampus and cortex of 10-month-old APPV717I transgenic mice. Pioglitazone treatment reduces the expression of the proinflammatory enzymes cyclooxygenase 2 (COX2) and inducible nitric oxide synthase (iNOS). Pioglitazone decreases beta-secretase-1 (BACE1) mRNA and protein levels, and also a 27% reduction in the levels of soluble Abeta1-42 peptide. [5]

Protocol

Solubility (25°C)

In vitro DMSO 10 mg/mL (28.05 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 356.44
Formula

C19H20N2O3S

CAS No. 111025-46-8
Storage powder
in solvent
Synonyms U 72107
Smiles CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04501406 Recruiting Drug: Pioglitazone|Other: Placebo Type 2 Diabetes Mellitus (T2DM)|Nonalcoholic Steatohepatitis University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) December 15 2020 Phase 2
NCT04535700 Recruiting Drug: Pioglitazone 30 mg|Other: standard of care Type 2 Diabetes Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal September 18 2020 Phase 4
NCT00904046 Recruiting Drug: Pioglitazone|Drug: Placebo Uric Acid Kidney Stone Disease University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Takeda Pharmaceuticals North America Inc. September 5 2019 Not Applicable
NCT04671056 Completed Drug: MGL-3196|Drug: Pioglitazone 15mg Healthy Madrigal Pharmaceuticals Inc. November 9 2018 Phase 1
NCT03501277 Completed Drug: Alogliptin|Drug: Pioglitazone|Drug: SYR-322-4833 BL Healthy Volunteers Takeda May 26 2018 Phase 1
NCT03471117 Recruiting Drug: Pioglitazone|Other: Placebo Chronic Kidney Diseases The University of Texas at Arlington|University of Texas Southwestern Medical Center at Dallas April 1 2018 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PPAR Signaling Pathway Map

Related PPAR Products

Tags: buy Pioglitazone (AD-4833) | Pioglitazone (AD-4833) ic50 | Pioglitazone (AD-4833) price | Pioglitazone (AD-4833) cost | Pioglitazone (AD-4833) solubility dmso | Pioglitazone (AD-4833) purchase | Pioglitazone (AD-4833) manufacturer | Pioglitazone (AD-4833) research buy | Pioglitazone (AD-4833) order | Pioglitazone (AD-4833) mouse | Pioglitazone (AD-4833) chemical structure | Pioglitazone (AD-4833) mw | Pioglitazone (AD-4833) molecular weight | Pioglitazone (AD-4833) datasheet | Pioglitazone (AD-4833) supplier | Pioglitazone (AD-4833) in vitro | Pioglitazone (AD-4833) cell line | Pioglitazone (AD-4833) concentration | Pioglitazone (AD-4833) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID